{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:02:10Z","timestamp":1794024130866,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences"},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242097"],"award-info":[{"award-number":["7242097"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01178-x","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T12:45:58Z","timestamp":1749127558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chimeric hemagglutinin and M2 mRNA vaccine for broad influenza subtype protection"],"prefix":"10.1038","volume":"10","author":[{"given":"Dongrong","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saisai","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelong","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-0411","authenticated-orcid":false,"given":"Shan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"1178_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285\u20131300 (2018).","journal-title":"Lancet"},{"key":"1178_CR2","doi-asserted-by":"publisher","first-page":"a038315","DOI":"10.1101\/cshperspect.a038315","volume":"11","author":"HQ McLean","year":"2021","unstructured":"McLean, H. Q. & Belongia, E. A. Influenza vaccine effectiveness: new insights and challenges.Cold Spring Harb. Perspect. Med 11, a038315 (2021).","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"1178_CR3","doi-asserted-by":"publisher","first-page":"E1701","DOI":"10.1073\/pnas.1525578113","volume":"113","author":"RA Neher","year":"2016","unstructured":"Neher, R. A., Bedford, T., Daniels, R. S., Russell, C. A. & Shraiman, B. I. Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses. Proc. Natl Acad. Sci. USA 113, E1701\u2013E1709 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1178_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature13087","volume":"507","author":"M Luksza","year":"2014","unstructured":"Luksza, M. & L\u00e4ssig, M. A predictive fitness model for influenza. Nature 507, 57\u201361 (2014).","journal-title":"Nature"},{"key":"1178_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(22)00982-5","volume":"400","author":"TM Uyeki","year":"2022","unstructured":"Uyeki, T. M., Hui, D. S., Zambon, M., Wentworth, D. E. & Monto, A. S. Influenza. Lancet 400, 693\u2013706 (2022).","journal-title":"Lancet"},{"key":"1178_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/infdis\/jiy103","volume":"218","author":"EJ Erbelding","year":"2018","unstructured":"Erbelding, E. J. et al. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J. Infect. Dis. 218, 347\u2013354 (2018).","journal-title":"J. Infect. Dis."},{"key":"1178_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.immuni.2017.09.007","volume":"47","author":"CI Paules","year":"2017","unstructured":"Paules, C. I., Marston, H. D., Eisinger, R. W., Baltimore, D. & Fauci, A. S. The pathway to a universal influenza vaccine. Immunity 47, 599\u2013603 (2017).","journal-title":"Immunity"},{"key":"1178_CR8","doi-asserted-by":"publisher","first-page":"e0075921","DOI":"10.1128\/JVI.00759-21","volume":"95","author":"AL Skarlupka","year":"2021","unstructured":"Skarlupka, A. L., Bebin-Blackwell, A. G., Sumner, S. F. & Ross, T. M. Universal influenza virus neuraminidase vaccine elicits protective immune responses against human seasonal and pre-pandemic strains. J. Virol. 95, e0075921 (2021).","journal-title":"J. Virol."},{"key":"1178_CR9","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1016\/j.vaccine.2021.06.072","volume":"39","author":"CY Lo","year":"2021","unstructured":"Lo, C. Y. et al. Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice. Vaccine 39, 4628\u20134640 (2021).","journal-title":"Vaccine"},{"key":"1178_CR10","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1128\/JVI.01715-13","volume":"87","author":"I Margine","year":"2013","unstructured":"Margine, I. et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87, 10435\u201310446 (2013).","journal-title":"J. Virol."},{"key":"1178_CR11","doi-asserted-by":"publisher","unstructured":"Steel, J. et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1, https:\/\/doi.org\/10.1128\/mbio.00018-10 (2010).","DOI":"10.1128\/mbio.00018-10"},{"key":"1178_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011514","volume":"19","author":"DM McCraw","year":"2023","unstructured":"McCraw, D. M. et al. Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes. PLoS Pathog. 19, e1011514 (2023).","journal-title":"PLoS Pathog."},{"key":"1178_CR13","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.immuni.2022.10.015","volume":"55","author":"SM Moin","year":"2022","unstructured":"Moin, S. M. et al. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. Immunity 55, 2405\u20132418.e7 (2022).","journal-title":"Immunity"},{"key":"1178_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"1178_CR15","doi-asserted-by":"publisher","first-page":"E2514","DOI":"10.1073\/pnas.1402766111","volume":"111","author":"VV Mallajosyula","year":"2014","unstructured":"Mallajosyula, V. V. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl Acad. Sci. USA 111, E2514\u2013E2523 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1178_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00498-6","volume":"7","author":"J Subbiah","year":"2022","unstructured":"Subbiah, J. et al. A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine. NPJ Vaccines 7, 68 (2022).","journal-title":"NPJ Vaccines"},{"key":"1178_CR17","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","volume":"349","author":"A Impagliazzo","year":"2015","unstructured":"Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301\u20131306 (2015).","journal-title":"Science"},{"key":"1178_CR18","doi-asserted-by":"publisher","first-page":"8178","DOI":"10.1128\/JVI.00627-06","volume":"80","author":"MF McCown","year":"2006","unstructured":"McCown, M. F. & Pekosz, A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J. Virol. 80, 8178\u20138189 (2006).","journal-title":"J. Virol."},{"key":"1178_CR19","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/13484","volume":"5","author":"S Neirynck","year":"1999","unstructured":"Neirynck, S. et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1157\u20131163 (1999).","journal-title":"Nat. Med."},{"key":"1178_CR20","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840\u2013854 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1178_CR21","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2666-5247(23)00216-1","volume":"4","author":"NHL Leung","year":"2023","unstructured":"Leung, N. H. L. et al. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial. Lancet Microbe 4, e670\u2013e682 (2023).","journal-title":"Lancet Microbe"},{"key":"1178_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2256422","volume":"12","author":"F Xiong","year":"2023","unstructured":"Xiong, F. et al. An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses. Emerg. Microbes Infect. 12, 2256422 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"1178_CR23","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569\u20131584 (2020).","journal-title":"Mol. Ther."},{"key":"1178_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32149-8","volume":"13","author":"N Pardi","year":"2022","unstructured":"Pardi, N. et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat. Commun. 13, 4677 (2022).","journal-title":"Nat. Commun."},{"key":"1178_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48555-z","volume":"15","author":"C Furey","year":"2024","unstructured":"Furey, C. et al. Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus. Nat. Commun. 15, 4350 (2024).","journal-title":"Nat. Commun."},{"key":"1178_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2202278","volume":"12","author":"N Ma","year":"2023","unstructured":"Ma, N. et al. Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence. Emerg. Microbes Infect. 12, 2202278 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"1178_CR27","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1016\/j.vaccine.2023.03.049","volume":"41","author":"S Xu","year":"2023","unstructured":"Xu, S., Zhang, B., Yao, J. & Ruan, W. A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection. Vaccine 41, 2905\u20132913 (2023).","journal-title":"Vaccine"},{"key":"1178_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39376-7","volume":"14","author":"IT Lee","year":"2023","unstructured":"Lee, I. T. et al. Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).","journal-title":"Nat. Commun."},{"key":"1178_CR29","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899\u2013904 (2022).","journal-title":"Science"},{"key":"1178_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. Influenza. Nat. Rev. Dis. Prim. 4, 3 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1178_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.chom.2010.05.009","volume":"7","author":"JK Taubenberger","year":"2010","unstructured":"Taubenberger, J. K. & Kash, J. C. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7, 440\u2013451 (2010).","journal-title":"Cell Host Microbe"},{"key":"1178_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2155072","volume":"12","author":"J Shi","year":"2023","unstructured":"Shi, J., Zeng, X., Cui, P., Yan, C. & Chen, H. Alarming situation of emerging H5 and H7 avian influenza and effective control strategies. Emerg. Microbes Infect. 12, 2155072 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"1178_CR33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.immuni.2013.09.013","volume":"39","author":"B Sl\u00fctter","year":"2013","unstructured":"Sl\u00fctter, B., Pewe, L. L., Kaech, S. M. & Harty, J. T. Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. Immunity 39, 939\u2013948 (2013).","journal-title":"Immunity"},{"key":"1178_CR34","doi-asserted-by":"publisher","first-page":"110456","DOI":"10.1016\/j.celrep.2022.110456","volume":"38","author":"T Schmit","year":"2022","unstructured":"Schmit, T. et al. Interferon-\u03b3 promotes monocyte-mediated lung injury during influenza infection. Cell Rep. 38, 110456 (2022).","journal-title":"Cell Rep."},{"key":"1178_CR35","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.4049\/jimmunol.1701543","volume":"200","author":"BM Coates","year":"2018","unstructured":"Coates, B. M. et al. Inflammatory monocytes drive influenza A virus-mediated lung injury in juvenile mice. J. Immunol. 200, 2391\u20132404 (2018).","journal-title":"J. Immunol."},{"key":"1178_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva, M. & O\u2019Garra, A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 10, 170\u2013181 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1178_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/mt.2012.246","volume":"21","author":"MC Kim","year":"2013","unstructured":"Kim, M. C. et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol. Ther. 21, 485\u2013492 (2013).","journal-title":"Mol. Ther."},{"key":"1178_CR38","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.1128\/JVI.00641-13","volume":"87","author":"F Krammer","year":"2013","unstructured":"Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542\u20136550 (2013).","journal-title":"J. Virol."},{"key":"1178_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00018-018-2935-4","volume":"76","author":"T Schlake","year":"2019","unstructured":"Schlake, T., Thess, A., Thran, M. & Jordan, I. mRNA as novel technology for passive immunotherapy. Cell Mol. Life Sci. 76, 301\u2013328 (2019).","journal-title":"Cell Mol. Life Sci."},{"key":"1178_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","volume":"23","author":"C Li","year":"2022","unstructured":"Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543\u2013555 (2022).","journal-title":"Nat. Immunol."},{"key":"1178_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11843-0","volume":"10","author":"J Schyns","year":"2019","unstructured":"Schyns, J. et al. Non-classical tissue monocytes and two functionally distinct populations of interstitial macrophages populate the mouse lung. Nat. Commun. 10, 3964 (2019).","journal-title":"Nat. Commun."},{"key":"1178_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39560-9","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters. Nat. Commun. 14, 4117 (2023).","journal-title":"Nat. Commun."},{"key":"1178_CR43","doi-asserted-by":"publisher","first-page":"eadg3469","DOI":"10.1126\/sciadv.adg3469","volume":"9","author":"MZM Zheng","year":"2023","unstructured":"Zheng, M. Z. M. et al. Single-cycle influenza virus vaccine generates lung CD8(+) Trm that cross-react against viral variants and subvert virus escape mutants. Sci. Adv. 9, eadg3469 (2023).","journal-title":"Sci. Adv."},{"key":"1178_CR44","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41577-021-00625-9","volume":"21","author":"JY Noh","year":"2021","unstructured":"Noh, J. Y., Jeong, H. W., Kim, J. H. & Shin, E. C. T cell-oriented strategies for controlling the COVID-19 pandemic. Nat. Rev. Immunol. 21, 687\u2013688 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1178_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011639","volume":"20","author":"LM Sircy","year":"2024","unstructured":"Sircy, L. M. et al. Generation of antigen-specific memory CD4 T cells by heterologous immunization enhances the magnitude of the germinal center response upon influenza infection. PLoS Pathog. 20, e1011639 (2024).","journal-title":"PLoS Pathog."},{"key":"1178_CR46","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85832","volume":"1","author":"KD Zens","year":"2016","unstructured":"Zens, K. D., Chen, J. K. & Farber, D. L. Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight 1, e85832 (2016).","journal-title":"JCI Insight"},{"key":"1178_CR47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature10851","volume":"483","author":"X Jiang","year":"2012","unstructured":"Jiang, X. et al. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 483, 227\u2013231 (2012).","journal-title":"Nature"},{"key":"1178_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07815-5","volume":"9","author":"EJ Grant","year":"2018","unstructured":"Grant, E. J. et al. Broad CD8(+) T cell cross-recognition of distinct influenza A strains in humans. Nat. Commun. 9, 5427 (2018).","journal-title":"Nat. Commun."},{"key":"1178_CR49","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.1128\/JVI.00519-10","volume":"84","author":"W Tu","year":"2010","unstructured":"Tu, W. et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J. Virol. 84, 6527\u20136535 (2010).","journal-title":"J. Virol."},{"key":"1178_CR50","doi-asserted-by":"publisher","first-page":"eadc9937","DOI":"10.1126\/sciadv.adc9937","volume":"8","author":"K van de Ven","year":"2022","unstructured":"van de Ven, K. et al. A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. Sci. Adv. 8, eadc9937 (2022).","journal-title":"Sci. Adv."},{"key":"1178_CR51","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.immuni.2022.05.007","volume":"55","author":"MG Alameh","year":"2022","unstructured":"Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 55, 1136\u20131138 (2022).","journal-title":"Immunity"},{"key":"1178_CR52","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke, R., Hogan, M. J., Lor\u00e9, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993\u20132005 (2022).","journal-title":"Immunity"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01178-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01178-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01178-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T13:01:45Z","timestamp":1749128505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01178-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01178-x","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C., Y.D. and D.Y. are co-inventors on pending patent applications related to the IAV mRNA vaccine. N.L., Q.Z., Y.D., C.H., L.H., C.C., Y.W., H.C. and W.Z. are employees of RinuaGene Biotechnology Co., Ltd. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}